Psoriasis im Kindes- und Jugendalter

• Literatur

• 1 Augustin M, Glaeske G, Radtke MA et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010; 162: 633-636
• 2 Swanbeck G, Inerot A, Martinsson T et al. Genetic counselling in psoriasis: empirical data on psoriasis among first-degree relatives of 3095 psoriatic probands. Br J Dermatol 1997; 137: 939-942
• 3 Bergboer JG, Oostveen AM, de Jager ME et al. Paediatric-onset psoriasis is associated with ERAP1 and IL23R loci, LCE3C_LCE3B deletion and HLA-C*06. Br J Dermatol 2012; 167: 922-925
• 4 Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes 2012; 2: e54
• 5 Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol 2013; 68: 654-662
• 6 Gutmark-Little I, Shah KN. Obesity and the metabolic syndrome in pediatric psoriasis. Clin Dermatol 2015; 33: 305-315
• 7 Kim GE, Seidler E, Kimball AB. Effect of Age at Diagnosis on Chronic Quality of Life and Long-Term Outcomes of Individuals with Psoriasis. Pediatr Dermatol 2015; 32: 656-662
• 8 Manzoni AP, Weber MB, Nagatomi AR et al. Assessing depression and anxiety in the caregivers of pediatric patients with chronic skin disorders. An Bras Dermatol 2013; 88: 894-899
• 9 Arakawa A, Siewert K, Stöhr J et al. Melanocyte antigen triggers autoimmunity in human psoriasis. J Exp Med 2015; 212: 2203-2212
• 10 Valdimarsson H, Thorleifsdottir RH, Sigurdardottir SL et al. Psoriasis – as an autoimmune disease caused by molecular mimicry. Trends Immunol 2009; 30: 494-501
• 11 Lande R, Botti E, Jandus C et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun 2014; 5: 5621
• 12 Griffiths CE, Christophers E, Barker JN et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol 2007; 156: 258-262
• 13 Höger PH, Hamm H. Psoriasis vulgaris bei Kindern und Jugendlichen. Pathogenese, Klinik und Therapie. Hautarzt 2015; 66: 267-276
• 14 Lewkowicz D, Gottlieb AB. Pediatric psoriasis and psoriatic arthritis. Dermatol Ther 2004; 17: 364-375
• 15 Burgos-Vargas R. The juvenile-onset spondyloarthritides. Rheum Dis Clin North Am 2002; 28: 531-560
• 16 Marrakchi S, Guigue P, Renshaw BR et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011; 365: 620-628
• 17 Trueb RM. Therapies for Childhood Psoriasis. Curr Probl Dermatol 2009; 38: 137-159
• 18 Ståhle M, Atakan N, Boehncke WH et al. Juvenile psoriasis and its clinical management: a European expert group consensus. J Dtsch Dermatol Ges 2010; 8: 812-818
• 19 Höger P. Kinderdermatologie: Differentialdiagnostik und Therapie bei Kindern und Jugendlichen. 3. Aufl. Stuttgart: Schattauer; 2011: 193,194
• 20 Sticherling M, Augustin M, Boehncke WH et al. Therapy of psoriasis in childhood and adolescence – a German expert consensus. J Dtsch Dermatol Ges 2011; 9: 815-823
• 21 de Jager ME, van de Kerkhof PC, de Jong EM et al. Dithranol therapy in childhood psoriasis: unjustifiably on the verge of falling into oblivion. Dermatology 2010; 220: 329-332
• 22 Jain VK, Aggarwal K, Jain K et al. Narrow-band UV-B phototherapy in childhood psoriasis. Int J Dermatol 2007; 46: 320-322
• 23 Thorleifsdottir RH, Sigurdardottir SL, Sigurgeirsson B et al. Improvement of psoriasis after tonsillectomy is associated with a decrease in the frequency of circulating T cells that recognize streptococcal determinants and homologous skin determinants. J Immunol 2012; 188: 5160-5165
• 24 de Jager ME, de Jong EM, van de Kerkhof PC et al. Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. J Am Acad Dermatol 2010; 62: 1013-1030
• 25 Pereira TM, Vieira AP, Fernandes JC et al. Cyclosporin A treatment in severe childhood psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 651-656
• 26 Reich K, Hartl C, Gambichler T et al. Retrospective data collection of psoriasis treatment with fumaric acid esters in children and adolescents in Germany (KIDS FUTURE study). J Dtsch Dermatol Ges 2016; 14: 50-58
• 27 Paller AS, Siegfried EC, Pariser DM et al. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol 2016; 74: 280-287 e1–3
• 28 Papp K, Gottlieb AB, Naldi L et al. Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol 2015; 14: 706-714
• 29 Papp K, Williams D, Thaci D et al. Study design and baseline characteristics from a phase 3, randomized, double-blind study of adalimumab versus methotrexate treatment in pediatric patients with chronic plaque psoriasis. Presented at: 72nd Annual Meeting of the American Academy of Dermatology; March 21–25, 2014. Denver:
• 30 Landells I, Marano C, Hsu MC et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol 2015; 73: 594-603